drugset
drugset / Trial / NCT02537938

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)

NCT02537938 ↗

Phase 1 Completed 24 enrolled NeuroGenetic Pharmaceuticals Inc WCCT Global · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study involves the use of an investigational drug called NGP 555. In each group of healthy subjects, 2 people will receive placebo and 6 people will receive NGP 555.

Timeline

Start
2016-01
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject NGP 555 Small molecule 100 mg Oral
Subject NGP 555 Small molecule 200 mg Oral
Subject NGP 555 Small molecule 400 mg Oral

Indications

Alzheimer disease